Ipilimumab/nivolumabImmune-related hepatitis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1807卷 / 1期

关键词：

D O I：

10.1007/s40278-020-79390-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：104 / 104

相关论文

共 50 条

[21] NivolumabImmune-related thyroiditis: 6 case reports
Reactions Weekly, 2018, 1727 (1) : 213 - 213
[22] NivolumabImmune-related hepatitis and pneumonia: case report
Reactions Weekly, 2022, 1932 (1) : 475 - 475
[23] NivolumabImmune-related adverse events: 19 case reports
Reactions Weekly, 2019, 1764 (1) : 251 - 251
[24] NivolumabImmune-related adverse events: 12 case reports
Reactions Weekly, 2020, 1785 (1) : 392 - 392
[25] NivolumabImmune-related dermatologic adverse reactions: 4 case reports
Reactions Weekly, 2017, 1636 (1) : 242 - 242
[26] NivolumabImmune-related meningoencephalitis: case report
Reactions Weekly, 2021, 1864 (1) : 307 - 307
[27] Methylprednisolone/nivolumabImmune-related hepatitis and lack of efficacy: case report
Reactions Weekly, 2022, 1909 (1) : 350 - 350
[28] NivolumabImmune-related gigantomastia: case report
Reactions Weekly, 2023, 1978 (1) : 294 - 294
[29] NivolumabImmune-related colitis: case report
Reactions Weekly, 2021, 1858 (1) : 307 - 307
[30] NivolumabImmune-related colitis: case report
Reactions Weekly, 2023, 1947 (1) : 321 - 321

← 1 2 3 4 5 →